These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 1706305)
1. The use of immunohistochemistry in metastatic prostatic adenocarcinoma to the breast. Green LK; Klima M Hum Pathol; 1991 Mar; 22(3):242-6. PubMed ID: 1706305 [TBL] [Abstract][Full Text] [Related]
2. [Immunohistochemical diagnosis of a case of metastatic prostate cancer to breast]. Gotoh A; Matsuura K; Yoshimura S; Takano Y Nihon Hinyokika Gakkai Zasshi; 1989 Dec; 80(12):1828-31. PubMed ID: 2483185 [TBL] [Abstract][Full Text] [Related]
3. Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy. Grignon D; Troster M Prostate; 1985; 7(2):195-202. PubMed ID: 2413432 [TBL] [Abstract][Full Text] [Related]
4. Breast metastases of prostatic carcinoma: immunohistochemical case study. Fukutani K; Kawabe K; Matsuki K; Endo H; Mikata N; Yokoyama M Urol Int; 1987; 42(5):395-7. PubMed ID: 2448938 [TBL] [Abstract][Full Text] [Related]
5. Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques. Svanholm H; Hørder M Scand J Urol Nephrol Suppl; 1988; 107():65-70. PubMed ID: 2453920 [TBL] [Abstract][Full Text] [Related]
6. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237 [TBL] [Abstract][Full Text] [Related]
7. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Sheridan T; Herawi M; Epstein JI; Illei PB Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190 [TBL] [Abstract][Full Text] [Related]
8. Carcinoma of prostate metastatic to breast. Drelichman A; Amer M; Pontes E; Al-Sarraf M; Vaitkevicius VK Urology; 1980 Sep; 16(3):250-5. PubMed ID: 7423701 [TBL] [Abstract][Full Text] [Related]
9. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer. Grob BM; Schellhammer PF; Brassil DN; Wright GL Urology; 1994 Oct; 44(4):525-9. PubMed ID: 7524238 [TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic antigen and carbohydrate antigen 19-9-producing adenocarcinoma of the prostate: report of an autopsy case. Kodama S; Itoh H; Ide H; Kataoka H; Takehara T; Nagano M; Hamasuna R; Koono M; Osada Y Urol Int; 1999; 63(3):193-7. PubMed ID: 10738193 [TBL] [Abstract][Full Text] [Related]
11. Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites. Stein BS; Vangore S; Petersen RO Urology; 1984 Aug; 24(2):146-52. PubMed ID: 6205496 [TBL] [Abstract][Full Text] [Related]
12. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study. Ersev A; Ersev D; Turkeri L; Ilker Y; Simsek F; Kullu S; Akdas A Prog Clin Biol Res; 1990; 357():129-34. PubMed ID: 1699237 [TBL] [Abstract][Full Text] [Related]
13. Adenosquamous carcinoma of prostate. Accetta PA; Gardner WA Urology; 1983 Jul; 22(1):73-5. PubMed ID: 6346632 [TBL] [Abstract][Full Text] [Related]
14. Immunohistologic diagnosis of 2 cases of metastatic prostate cancer to breast. Naritoku WY; Taylor CR J Urol; 1983 Aug; 130(2):365-7. PubMed ID: 6192256 [TBL] [Abstract][Full Text] [Related]
15. Correlation between tissular levels of prostatic acid phosphatase and prostate-specific antigen and hormonal response of metastatic prostatic cancer. Algaba F; Chéchile G; Zungri E Eur Urol; 1988; 14(6):470-3. PubMed ID: 2460355 [TBL] [Abstract][Full Text] [Related]
16. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Osunkoya AO; Epstein JI Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186 [TBL] [Abstract][Full Text] [Related]
17. Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). Garde SV; Sheth AR; Venkatesan VM; Panchal CJ; Porter AT; Grignon DJ Cancer Lett; 1994 Apr; 78(1-3):11-7. PubMed ID: 7514089 [TBL] [Abstract][Full Text] [Related]
18. Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases. Mai KT; Commons AS; Perkins DG; Yazdi HM; Collins JP Hum Pathol; 1996 Dec; 27(12):1377-81. PubMed ID: 8958315 [TBL] [Abstract][Full Text] [Related]
19. Bilateral breast metastases from oat-cell lung carcinoma in a man treated with diethylstilbestrol for prostatic adenocarcinoma. Giarelli L; Ferlito A J Am Geriatr Soc; 1976 Nov; 24(11):511-5. PubMed ID: 184140 [No Abstract] [Full Text] [Related]
20. DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma. Berner A; Waere H; Nesland JM; Paus E; Danielsen HE; Fosså SD Br J Urol; 1995 Jan; 75(1):26-32. PubMed ID: 7531589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]